FDA Hits Aurobindo for Computer Controls, Documentation Issues

Drug Industry Daily
A A
The FDA cited drug manufacturer Aurobindo Pharma for inadequate computer access controls and written procedures.

To View This Article:

Login

Subscribe To Drug Industry Daily